Peginesatide Acetate is a synthetic, PEGylated peptide-based erythropoiesis-stimulating agent that was historically developed to treat anemia associated with chronic kidney disease in adult patients undergoing… Read more
Peginesatide Acetate is a synthetic, PEGylated peptide-based erythropoiesis-stimulating agent that was historically developed to treat anemia associated with chronic kidney disease in adult patients undergoing dialysis. As a specialized pharmaceutical compound, it functions by stimulating red blood cell production through the activation of the erythropoietin receptor. Within analytical and research settings, high-quality reference standards of this drug, alongside its corresponding impurities, metabolites, and stable isotope-labelled compounds, are essential for rigorous quality control. These materials facilitate precise impurity profiling, enabling laboratories to conduct accurate analytical testing and method validation for development and regulatory compliance. The use of stable isotope-labelled standards is particularly valuable for the accurate quantification of drug-related components in complex biological matrices, ensuring robust analysis during metabolic studies and toxicological evaluations throughout the pharmaceutical development process.